BenzingaOctober 15, 2026 at 10:06 AM NY12 Days Ago
Why Is Arcutis Biotherapeutics Stock Surging Thursday?
Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
